Atea Pharmaceuticals (NASDAQ:AVIR) Issues Earnings Results, Beats Expectations By $0.11 EPS

Atea Pharmaceuticals (NASDAQ:AVIR) posted its quarterly earnings data on Monday. The company reported ($0.40) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.51) by $0.11, FiscalAI reports.

Here are the key takeaways from Atea Pharmaceuticals’ conference call:

• Atea reported that its phase III C-BEYOND trial met its primary and secondary endpoints: bemnifosbuvir/ruzasvir achieved a 94% SVR rate versus 95% for standard-of-care SOF/VEL, meeting the prespecified non-inferiority margin. The company highlighted the eight-week course for non-cirrhotic patients and said adverse events were comparable between treatment arms.
• The next major HCV milestone is top-line data from the global C-FORWARD trial, expected in early 2027; if results are positive, Atea is targeting an NDA submission in mid-2027. The filing timeline therefore remains contingent on the upcoming readout.
• Atea ended September with $191.2 million in cash and marketable securities and closed a Hercules Capital facility with a $65 million initial draw and up to $135 million in additional funding, subject to conditions. Management expects current resources and the initial draw to fund operations into mid-2028 and said the facility could support commercialization without equity financing.
• Commercial preparation is underway, but Atea said it has not yet begun payer discussions because the product is not approved; it is currently assessing coverage and formulary dynamics. The company also said a pending HCV elimination bill is unlikely to be an early priority in the new Congress and would need to be reintroduced.

Atea Pharmaceuticals Price Performance

Shares of NASDAQ:AVIR traded up $0.01 during trading on Wednesday, reaching $4.21. 79,612 shares of the company were exchanged, compared to its average volume of 381,400. The firm has a market capitalization of $338.09 million, a PE ratio of -2.16 and a beta of 0.76. The business’s fifty day simple moving average is $4.88 and its 200-day simple moving average is $4.93. Atea Pharmaceuticals has a 12-month low of $2.87 and a 12-month high of $6.45.

Analyst Upgrades and Downgrades

AVIR has been the topic of a number of analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Atea Pharmaceuticals in a research note on Thursday, October 15th. Wall Street Zen raised Atea Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, September 12th. Finally, Morgan Stanley raised their price target on Atea Pharmaceuticals from $6.00 to $7.00 and gave the stock an “equal weight” rating in a research note on Thursday, August 13th. One research analyst has rated the stock with a Strong Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Atea Pharmaceuticals currently has an average rating of “Hold” and an average target price of $7.00.

Atea Pharmaceuticals Company Profile

Atea Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing oral antiviral therapies for serious infectious diseases. The company’s research platform is based on nucleotide and nucleoside prodrug technologies designed to target viral replication. Atea’s lead product candidate is bemnifosbuvir, formerly known as AT-527, an orally administered antiviral that has been evaluated for the treatment of COVID-19. The company has also investigated bemnifosbuvir and related antiviral approaches for other viral infections, including hepatitis C. Development programs and strategic priorities may change as clinical studies and regulatory reviews progress.